CSBio CSBio

X
[{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, COVID-19 Preventive Vaccine, GX-19, clinical 1\/2 Phase Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Expected to Apply for Approval of Covid-19 Vaccine Next Fall","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Genexine"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax, SK bioscience Collaborate for COVID-19 Vax Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Extend Collaboration to Develop \u2018Next Generation\u2019 Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$26.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Expand Partnership to Develop Vaccine Against Covid-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$210.1 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Expand Partnership to Advance Multiple COVID-19 Variant Vaccines and Scale-Up Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and SK bioscience's COVID Vaccine Submitted for S.Korea Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Korea Institute of Science and Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"EuBiologics"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Hanmi Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Protein-based SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising titres compared to a control vaccine and clinically favourable safety profile.

            Lead Product(s): GBP510

            Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovione

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: GSK

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested.

            Lead Product(s): EuCorVac-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Korea Institute of Science and Technology

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funding will support Phase 3 trials of SK bioscience’s recombinant protein vaccine candidate (GBP510) and adaptation for use against multiple variants of concern.

            Lead Product(s): GBP510

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $210.1 million Upfront Cash: Undisclosed

            Deal Type: Funding May 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of doses by 2022.

            Lead Product(s): GX-19N

            Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19N

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Genexine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CEPI will provide up to $14.2 million to support the adaptation of SK bioscience’s recombinant protein vaccine candidate (GBP510) for use against “variants of concern”, such as the B.1.351 variant first identified in South Africa.

            Lead Product(s): GBP510

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $26.7 million Upfront Cash: Undisclosed

            Deal Type: Funding March 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CEPI will contribute up to $10 million towards the cost of a phase I/II study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials.

            Lead Product(s): GBP510

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration December 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Genexine expects to obtain full data from a Phase I trial of its DNA vaccine GX-19 late this year or early next year, while starting a Phase IIa study within this year and concurrent Phase IIb and III trials in the first half of next year.

            Lead Product(s): GX-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period. NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2.

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Novavax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            First domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the Ministry of Food and Drug Safety.

            Lead Product(s): GX-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY